TY - JOUR T1 - Serum periostin and eotaxin-2 as promising biomarkers in asthmatic smokers JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.congress-2021.PA1135 VL - 58 IS - suppl 65 SP - PA1135 AU - Saher Farghly AU - Atef Farouk El-Karn AU - Mahmoud Farouk Sherif AU - Mohamed Ismail Seddik AU - Safaa Abdelgayed AU - Mohammed Abdelghany Y1 - 2021/09/05 UR - http://erj.ersjournals.com/content/58/suppl_65/PA1135.abstract N2 - Serum periostin and eotaxin-2 as promising biomarkers in asthmatic smokers.Background: Smoking influence many changes in asthmatic airway inflammation by stimulating the production of certain cytokines. Serum periostin and eotaxin-2 in asthmatic patients are affected by smoking.Objectives: The purpose of this study was to study serum periostin and eotaxin-2 level in asthmatic smokers.Patients and methods: The present observational, cross sectional study was conducted at Chest department in Assiut university hospital, during the period from August 2018 to January 2020. Hundred and seventeen asthmatic patients (42 smokers, 30 ex-smokers and 45 non-smokers) were studied for serum periostin and eotaxin-2 (ELISA). The effects of smoking status and inflammatory biomarkers including sputum eosinophilic and neutrophilic count on serum level of periostin and eotaxin-2 in asthmatic patients were analysed.Results: Serum periostin was significantly higher in non-smokers in comparison to smokers and ex-smokers. However, serum eotaxin-2 was significantly higher among smokers in comparison to non-smokers and ex-smokers. Serum periostin had negative correlation with smoking index, and positive correlation with eosinophils count, while serum eotaxin-2 had positive correlation with smoking index, eosinophilic and neutrophilic count in sputum.Conclusion: Asthmatic smokers represent a distinct phenotype of the disease. This inflammatory phenotype seen in smokers with asthma showed increased serum eotaxin-2 and low serum periostin.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1135.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only). ER -